GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (LTS:0I3Q) » Definitions » Cyclically Adjusted Price-to-FCF

Corcept Therapeutics (LTS:0I3Q) Cyclically Adjusted Price-to-FCF : 33.35 (As of May. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Corcept Therapeutics Cyclically Adjusted Price-to-FCF?

As of today (2024-05-22), Corcept Therapeutics's current share price is $28.6772. Corcept Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $0.86. Corcept Therapeutics's Cyclically Adjusted Price-to-FCF for today is 33.35.

The historical rank and industry rank for Corcept Therapeutics's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

LTS:0I3Q' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 26.51   Med: 51.24   Max: 411
Current: 33.54

During the past years, Corcept Therapeutics's highest Cyclically Adjusted Price-to-FCF was 411.00. The lowest was 26.51. And the median was 51.24.

LTS:0I3Q's Cyclically Adjusted Price-to-FCF is ranked better than
71.84% of 103 companies
in the Biotechnology industry
Industry Median: 56.6 vs LTS:0I3Q: 33.54

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Corcept Therapeutics's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $0.216. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.86 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Corcept Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Corcept Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Cyclically Adjusted Price-to-FCF Chart

Corcept Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 144.70 106.40 44.99 32.58 40.21

Corcept Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.25 30.50 34.27 40.21 29.33

Competitive Comparison of Corcept Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Corcept Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corcept Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Corcept Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Corcept Therapeutics's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=28.6772/0.86
=33.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Corcept Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.216/131.7762*131.7762
=0.216

Current CPI (Mar. 2024) = 131.7762.

Corcept Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.089 100.560 -0.117
201409 -0.059 100.428 -0.077
201412 -0.014 99.070 -0.019
201503 -0.018 99.621 -0.024
201506 -0.001 100.684 -0.001
201509 0.008 100.392 0.011
201512 0.038 99.792 0.050
201603 0.030 100.470 0.039
201606 0.014 101.688 0.018
201609 0.076 101.861 0.098
201612 0.038 101.863 0.049
201703 0.078 102.862 0.100
201706 0.125 103.349 0.159
201709 0.086 104.136 0.109
201712 0.194 104.011 0.246
201803 0.269 105.290 0.337
201806 0.119 106.317 0.147
201809 0.352 106.507 0.436
201812 0.171 105.998 0.213
201903 0.189 107.251 0.232
201906 0.206 108.070 0.251
201909 0.313 108.329 0.381
201912 0.393 108.420 0.478
202003 0.272 108.902 0.329
202006 0.431 108.767 0.522
202009 0.239 109.815 0.287
202012 0.273 109.897 0.327
202103 0.195 111.754 0.230
202106 0.349 114.631 0.401
202109 0.388 115.734 0.442
202112 0.404 117.630 0.453
202203 0.306 121.301 0.332
202206 0.156 125.017 0.164
202209 0.286 125.227 0.301
202212 0.287 125.222 0.302
202303 0.225 127.348 0.233
202306 0.386 128.729 0.395
202309 0.476 129.860 0.483
202312 0.053 129.419 0.054
202403 0.216 131.776 0.216

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Corcept Therapeutics  (LTS:0I3Q) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Corcept Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Corcept Therapeutics (LTS:0I3Q) Business Description

Traded in Other Exchanges
Address
149 Commonwealth Drive, Menlo Park, CA, USA, 94025
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Corcept Therapeutics (LTS:0I3Q) Headlines

No Headlines